Download Free Medical Medication Assisted Treatment PowerPoint Presentation

Medication Assisted Treatment PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical PowerPoint presentation titled "Medication Assisted Treatment" by Daniel T. Brown, D.O., Medical Director, Meridian HealthCare, to learn about the history of Opiate Addiction, Physiology of Opiate Addiction, Evidence in Support of MAT, Medications used in Medication Assisted Treatment (Methadone, Buprenorphine, Naltrexone and Naloxone). Medication-Assisted Treatment (MAT) is a treatment approach used for individuals who are struggling with substance abuse or addiction. MAT combines the use of medication, such as methadone, buprenorphine, or naltrexone, with counseling and behavioral therapy. The goal of MAT is to help individuals with addiction to reduce or stop their drug use, decrease their risk of overdose, and improve their overall quality of life. The medication used in MAT can help to manage withdrawal symptoms and cravings, making it easier for individuals to engage in therapy and address the underlying causes of their addiction.

Tags : Medication Assisted Treatment, Opiate Addiction, Physiology of Opiate Addiction, MAT, Medications used in Medication Assisted Treatment, Methadone, Buprenorphine, Naltrexone, Naloxone, substance abuse, addiction

Published on : Mar 14, 2023 | Views : 787 | Downloads : 0

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Medication Assisted Treatment Daniel T. Brown, D.O. Medical Director, Meridian HealthCare
Slide 2-

Objectives Enhance understanding of: History of Opiate Addiction Physiology of Opiate Addiction Evidence in Support of MAT Medications used in Medication Assisted Treatment: Methadone Buprenorphine Naltrexone Naloxone
Slide 3-

ppt slide no 3 content not found
Slide 4-

ppt slide no 4 content not found
Slide 5-

Early Treatment Attempts By 1900, some physicians were attempting to treat opiate addicts with tapering doses of morphine or heroin. By 1914 it was estimated that one in 400 Americans were addicted to opiates. New York Department of Health established a clinic to treat opiate addicts with weaning doses. 1919 All early attempts at MAT ended by due to Harrison Act. 1935 “The Narcotic Farm” (97% relapse rates) 1960’s Civil Commitment (5 out of 6 relapsed)
Slide 6-

Beginning of MedicationAssisted Treatment 1950’s to 1970’s, prisons overcrowded with drug abusers, crime rates were high and overdose deaths were rising. AMA and American Bar Association joint proposal for the formation of OTPs (1958) By 1965 first methadone programs were started as research. Initial programs showed great response in retention in treatment, reduction in crime and reduction in drug use. By 1970 the Nixon administration greatly increased funding to expand Opioid Treatment Programs.
Slide 7-

Neurophysiology ofOpioid Dependence The Locus Ceruleus produces Noradrenaline which stimulates wakefulness, breathing, blood pressure, general alertness and other functions. Opiates link to Mu receptors in the LC and suppress the release of NA resulting in drowsiness, slowed respirations, low BP, etc. LC neurons chronically exposed to opiates adapt and produce normal levels of NA even when opiates are present. In the absence of opiates these neurons release excessive amounts of NA resulting in withdrawal symptoms (anxiety, muscle cramps, diarrhea, restlessness).
Slide 8-

Neurophysiology of Opioid Addiction Stimulation of Mesolimbic (Midbrain) Reward System. Signals Ventral Tegmental Area (VTA) which causes release of Dopamine (DA) into the Nucleus Accumbens resulting in euphoria. Form associations linking euphoria to persons, places, smells, sounds, etc. Cravings are stimulated by these associations.
Slide 9-

Why are we treating OpioidAddiction with Opioids?! Why don’t we treat Alcohol Use Disorders with Alcohol? Cocaine? Benzodiazepines? Important to understand unique aspects of Opioid Addiction. Lethality of Disease Severity and length of Acute withdrawal symptoms Protracted Post-Acute withdrawal syndrome with cravings lasting > 1 year Highest rates of relapse Association with Criminal Activity Association with transmission of Infectious Disease
Slide 10-

Important Concepts forUnderstanding MAT Addiction vs. Dependence – Absence of harm and the pathological pursuit of the substance Medical Futility Risk vs. Benefit NO Punitive role for Addiction Medicine Providers Treatment based on best available medical evidence. Must not treat based on personal beliefs!
Slide 11-

Benefits of MAT Decreased risk of Hepatitis C, HIV transmission Decreased criminal activity as well as risk of becoming a victim of violent crime. For Pregnant patients, decreased risk of low birth weight, premature birth and obstetric complications. Improves retention in treatment and decreases relapse rates. Decreased risk of death (all causes) 15X !!!!
Slide 12-

Methadone Synthetic Opioid developed in Germany in 1937 Full Agonist of Mu receptor Mean elimination half-life 22hours First used in MAT in 1960’s Used in liquid form (10mg/1ml) for MAT
Slide 13-

Methadone Disadvantages High variability in elimination half-life Tolerance with chronic use Side effects of weight gain, apathy Prolongation of QT interval at higher doses Many drug interactions Intoxication/impairment at higher plasma levels
Slide 14-

Methadone Advantages Daily dosing required Improved retention in treatment Less Diversion Easily adjusted dose (1mg increments) Cost
Slide 15-

ppt slide no 15 content not found
Slide 16-

Buprenorphine Developed to be a less habit-forming opioid by Reckitt & Colman Initially released in injection form in 1978 for acute pain in ER setting. Only used in Europe. Sublingual form developed in 1982 FDA approved in 2002 for treatment of opioid dependence Initially physicians were only allowed to treat 10 patients. 2006 increased to 100 patients.
Slide 17-

Buprenorphine Partial Agonist of Mu receptor Mean elimination half-life of 37 hours Available in several forms Suboxone films (buprenorphine/naloxone) 8mg/2mg and 2mg/0.5mg Suboxone sublingual tablets Subutex (buprenorphine) 8mg/2mg Zubsolv sublingual tablets 5.7/1.4mg and 1.4/0.36 Bunavail buccal films 2.1/0.3, 4.2/0.7, 6.3/1mg
Slide 18-

ppt slide no 18 content not found
Slide 19-

Buprenorphine Disadvantages Must wait until patient is in full withdrawal or risk precipitated withdrawal. Potential for Hepatic Dysfunction Side effect of nausea in some patients Dosing adjustments are limited in tablet form Expensive Limited to 100 patients per physician license Lack of long-term data on infant and child effects. Clinically significant increase in drop-out rates compared to Methadone. Increased Risk of Diversion
Slide 20-

Buprenorphine Advantages Partial Agonist with “ceiling effect” and lower risk of overdose. Less Tolerance. Fewer Drug Interactions. When combined with naloxone, IV abuse is deterred. “Functional Antagonist” due to high affinity for Mu receptor. Patients are eligible for “take-home” dosing on day one of treatment, which allows for split dosing without daily visits. Evidence of Less Severe NAS
Slide 21-

Neonatal Abstinence Syndrome “neonatal syndrome is an expected and treatable condition that follow prenatal exposure to opioid agonists…” (Joint Committee Opinion of ACOG and ASAM) Methadone exposed infants may begin withdrawal symptoms anytime in the first 2 weeks of life but usually appear by 72 hours. Buprenorphine exposed infants generally develop symptoms within 12-48 hours, peak at 72-96 hours and resolve by 7 days. No evidence of correlation between severity of NAS and dose of methadone.
Slide 22-

How do we choose the appropriate MAT Medication for our patients? All patients should be initially treated with buprenorphine unless: Previous treatment failure with buprenorphine Unstable environment with high risk of diversion Currently on Methadone
Slide 23-

Naltrexone Therapy: Oral Tablet: 25-50mg daily – usually lasts 24-48 hrs First discovered in 1963; FDA approved in 1984 to treat opioid dependence. Vivitrol Injection: Once-monthly 380mg IM injection FDA approved in 2010 for opioid dependence
Slide 24-

Naltrexone Therapy Advantages: Prevents relapse by blocking access to Mu Receptor Substantially reduces cravings Not addictive No withdrawal symptoms Very few side effects
Slide 25-

Naltrexone Therapy Disadvantages: Poor retention in treatment Patients must detox before treatment Opioid free 7-10 days minimum Methadone and Suboxone 14 days Patients who relapse after Naltrexone therapy have lower tolerance and may be at increased risk of overdose.
Slide 26-

ppt slide no 26 content not found
Slide 27-

Why am I willing to prescribe MAT for long periods of time? Evidence Based Medicine supports a minimum of 18 months of treatment to achieve desired outcomes. Patients who are participating in programs, invested in their recovery and stable on a dose of buprenorphine have NO risk to reward benefit from stopping MAT. Patients who are forced to taper from buprenorphine have increased risk of relapse and therefore increase risk of death. Name one other instance where physicians stop prescribing an effective medication and cause an increase in their patient’s mortality rate.
Slide 28-

ppt slide no 28 content not found